WO2000073493A2 - A nematode drug screen for modulators of mammalian disorders - Google Patents
A nematode drug screen for modulators of mammalian disorders Download PDFInfo
- Publication number
- WO2000073493A2 WO2000073493A2 PCT/US2000/014678 US0014678W WO0073493A2 WO 2000073493 A2 WO2000073493 A2 WO 2000073493A2 US 0014678 W US0014678 W US 0014678W WO 0073493 A2 WO0073493 A2 WO 0073493A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- elegans
- egl
- activity
- compounds
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
- G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
- G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
- G01N2400/24—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar beta-D-Glucans, i.e. having beta 1,n (n=3,4,6) linkages between saccharide units, e.g. xanthan
- G01N2400/28—Chitin, chitosan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the invention relates to efficient screening methods for the identification of compounds capable of inhibiting egg laying in C. elegans and to methods for the identification of compounds capable of inhibiting APP processing in mammalian cells.
- the invention further relates to the identified compounds and methods for using those compounds.
- AD Alzheimer's disease
- WO 97/48983 a degenerative neurological disorder that results in a progressive loss of mental faculties, ultimately leading to dementia and death.
- this disease afflicts 2-3 million people in the U.S. alone (WO 97/48983); today, the estimated figure has swollen to 4 million people, with an estimated annual treatment cost of 90 billion U.S. dollars.
- the development of rapid methods for screening candidate compounds for efficacy as therapeutics presents a promising avenue for lowering those costs.
- the progressive dementia associated with AD is associated with the formation of amyloid plaques and neurofibrillary tangles, accompanied by gliosis and neuronal loss.
- Three genes have been discovered to date which, when mutated, result in an autosomal dominant form of the disease (Lendon et al.,
- proteases responsible for cleaving APP, or a processed form of APP, at the N- and C-termini to generate the A ⁇ peptide have been termed ⁇ -secretase and ⁇ -secretase, respectively.
- the ⁇ -secretase recently was found by comparing the nematode genome with human expressed sequence tags (ESTs), see Yan et al., Nature 402:533-37 (1999); the ⁇ -secretase may be associated with presenilins (DeStrooper et al., Nature 391 :387-90 (1998). Formation of the longer, 42-amino-acid form of the peptide is associated with accelerated AD pathogenesis.
- APP, PS1 or PS2 increase the ratio of A ⁇ 1-42 relative to total A ⁇ peptide production by subtly altering the site of ⁇ -secretase processing (Citron et al., 1997).
- the cleavage site for ⁇ -secretase processing is unusual in that it is located within the APP transmembrane domain.
- Insight into presenilin function has come from genetic studies of presenilin genes in model organisms such as the nematode, Caenorhabditis elegans, and from engineered deletions of the PS1 gene in mice. Three presenilin genes have been identified in C.
- a third major health problem for human populations is cancer.
- cancer A third major health problem for human populations is cancer.
- a great va ⁇ ety of cancers have been identified and, notwithstanding our incomplete understanding, there appear to be a number of causative agents.
- One significant cont ⁇ butor to the development of cancer is genetic predisposition, as evidenced by the research conducted on cellular oncogenes
- One well-studied example is the ras oncogene, which encodes a protein that interferes with the control of normal cell growth and development.
- elegans to lay eggs (Trent et al., Genetics 104:619-47 (1983)). These genes include a large group of egl (egg laying defect) genes, as well as other genes. Collectively, mutations in apparent mammalian counterparts to members of this group of genes have been associated with a variety of mammalian disorders and diseases, including Alzheimer's disease, cardiopulmonary disease, and Ras- induced cancer.
- the genome of C. elegans contains three orthologs of the Alzheimer's disease presenilin genes.
- loss of presenilin function causes a defect in egg laying.
- loss of presenilin- 1 (PS 1 ) function blocks amyloid beta peptide processing from the amyloid protein precursor (APP), as noted above.
- APP amyloid protein precursor
- Ras farnesyltransferase block the multivulva phenotype caused by an activating mutation in the ras gene (Hara et al., Proc. Natl. Acad. Sci. (USA) 92:3333-37 (1994)).
- the ras gene is known to be an oncogene involved in many human tumors, and inhibitois of human Ras farnesyltianserase are attractive as candidate anticancer drugs
- methods of screening for therapeutics that aie based on the egg laying behavior of the free-living nematode C elegans appear to provide a broad- spectrum set of assays designed to identify compounds that are risk factors for the development of a mammalian disorder or disease, as well as to identify potential therapeutics effective in treating a va ⁇ ety of mammalian diseases/disorders, such as Alzheimer's disease, cardiopulmonary disease and cancer, among others
- One way to discover such ⁇ sk factors is to measure the ability of test compounds to inhibit the egg laying of wild-type animals, one way to discover potential therapeutics, or drugs, is to revert the phenotype of egg laying deficient mutants to the wild-type
- the currently used method for measu ⁇ ng egg laying is visual examination, under a microscope, of a large number of worms to determine if eggs are being shed into the environment or are hatching mside the hermaphroditic parent (mtra-parent hatching indicates that eggs are not
- the assay can be easily adapted for high-throughput screening of candidate therapeutics or drugs
- a need continues to exist in the art for rapid and efficient methods of screening candidate compounds that modulate egg laying behavior m nematodes and/or modulate the progress of one or more mammalian disorders or diseases, such as Alzheimer's disease (e g , modulation of APP processing), cardiopulmonary disease (e g , modulation of potassium channel function), and cancer (e g , modulation of Ras function), among others
- a need also continues to exist for the candidate therapeutics themselves, as well as methods of using those compounds to treat mammalian disorders and diseases
- the invention satisfies one or more of the aforementioned needs in the art by providing rapid and versatile methods of screening for candidate compounds effective in treating any one or more of a variety of mammalian disorders and diseases, such as Alzheimer's disease, cardiopulmonary disease and cancer.
- mammalian disorders and diseases such as Alzheimer's disease, cardiopulmonary disease and cancer.
- these methods which are readily adaptable to high throughput formats, enjoy the advantage of rapidly, albeit indirectly, measuring the egg laying behavior of nematodes such as Caenorhabditis elegans by determining the level of chitinase released into the culture medium.
- the methods of the invention combine the positive correlation of nematode egg laying behavior and mammalian disorders or disease states with the rapid and sensitive assay of chitinase activity released into worm culture media.
- one aspect of the invention is drawn to a method of identifying an egg laying deficiency in Caenorhabditis elegans comprising monitoring the chitinase activity in the medium of a C. elegans culture, the egg laying deficiency being identified as a decreased chitinase activity in the medium as compared to the chitinase activity in the medium of a C. elegans culture free of any egg laying defect.
- Another aspect of the invention is directed to a method of screening for a compound that mitigates an egg laying deficiency in C. elegans, comprising: (a) providing a culture of C. elegans comprising a non- wild-type allele of a gene associated with an egg laying deficiency; and (b) monitoring the chitinase activity in the medium of the culture in the absence and presence of a candidate compound, wherein a candidate compound that increases chitinase activity is identified as a compound that mitigates the egg laying defect.
- Suitable genes for use in this aspect of the invention include, but are not limited to, a gene selected from the group consisting of a gene in the presenilin pathway (e.g., sel-12, hop-1, and spe- 4), egl- , egl-5, egl-26/cog-4, egl- 38, egl-43. egl-44, egl-46. sen ⁇ -1. sem-2, sem-4, rab-3, unc-31. egl-22. unc-51, lin-17, egl-20. egl-27, bar- 1, egl- 15. egl-1 7. unc-53.
- a gene in the presenilin pathway e.g., sel-12, hop-1, and spe- 4
- egl- e.gl-5, egl-26/cog-4, egl- 38, egl-43. egl-
- ⁇ nc-40 egl-8, egl-10. egl-30. ⁇ nx-1, in.x-2. daf-4, daf-8. da/- 14. daf-7. egl-4. egl-32. lin-12(gf), let-60, lin-3, let-23, sem-5, lin-45, li ⁇ -39, lin-l, lin-31, lin-2.
- a preferred concentration range for a candidate compound present in a nematode culture is 0.03 to 30 micromolar; another preferred concentration range for a candidate compound is 0.03 to 10 micromolar.
- a related aspect of the invention provides a method of screening for a compound that modulates a mammalian disorder, comprising: (a) identifying a compound that mitigates an egg laying defect in C. elegans according to the method described above, (b) contacting a mammalian cell or cells exhibiting a trait characteristic of a disorder selected from the group consisting of Alzheimer's disease, Ras-inducible cancer, and a potassium channel disorder with the compound; and (c) monitoring the cell or cells in the presence and absence of the compound, wherein a compound that reduces at least one trait of the disorder is identified as a compound that modulates the disorder.
- a trait characteristic of a disorder is APP processing, or production of an amyloid ⁇ peptide.
- the mammalian cell or cells of the invention may be found in culture, or may be found in an intact mammal; an exemplary mammalian cell is a human cell.
- the invention is drawn to the above- described method further comprising a step of manufacturing a composition comprising a compound identified according to step (c) of the method described immediately above as a compound that modulates the disorder, and a pharmaceutically acceptable carrier.
- the invention contemplates methods for modulating mammalian disorders comprising administering to a mammal an effective amount of a composition manufactured according to the method described in the pieceding sentence An exemplai) mammal to w hich these compositions ma ⁇ be admimsteied is a human
- the invention is directed to the compound identified as a modulator of a mammalian disorder desc ⁇ bed e
- a modulator of a mammalian disorder desc ⁇ bed e Such a compound may modulate presenilin activity and may be found in a pharmaceutical composition comprising the compound m a dosage effective in treating a mammalian disorder selected from the group consisting of Alzheimer's disease, Ras-inducible cancer and potassium transport disorders
- Another aspect of the invention is drawn to a method of identifying an inhibitor of C elegans egg laying, comp ⁇ sing (a) providing a culture of C elegans, (b) measuring the chitinase activity in the medium of the culture in the absence and presence of a candidate compound, and (c) identifying as an inhibitor, a candidate compound that produces a decrease in the chitmase activity in the medium when present as compared to the chitmase activity in the medium in the absence of the candidate compound
- a related aspect of the invention is the above- desc ⁇ bed method further comp ⁇ sing determining whether the candidate compound modulates one or more of the following ⁇ -amyloid plaque formation in a mammal, APP processing in a mammalian cell that expresses APP, the activity of a component of the presenilin pathway, or the activity of a component of the C elegans Notch pathway, such as Glp-1 or Lm-12
- Figure 1 shows the compa ⁇ son of the wild-type (N2), DT6716 (eg -36) and SG1214(.ye/-12) strains of C elegans in asynchronous culture with regard to chitmase release
- the released chitmase activity in the eg -36 and se/-12 strains of C elegans is s ⁇ gn ⁇ ficantly(p ⁇ 0 0001) lower than in the wild-type strain
- Figure 2 shows the percent variation (positive numbers-stimulation, negative numbers- inhibition) of chitinase release by va ⁇ ous test compounds
- Figure 3 illustrates the frequency distribution for the percent va ⁇ ation (positive numbers- stimulation, negative numbers- inhibition) of chitmase release by va ⁇ ous test compounds Approximately 110 compounds cluster between -5 and -10% inhibition of chitmase activity m culture supematants
- Figure 4 shows the percent va ⁇ ation (positive numbers- stimulation, negative numbers- inhibition) of chitmase enzyme activity by va ⁇ ous test compounds
- Figure 5 illustrates the frequency distribution for the percent va ⁇ ation (positive numbers- stimulation, negative numbers- inhibition) of chitmase enzyme act ⁇ ity bv ⁇ a ⁇ ous test compounds Appioximately 225 compounds cluster around -20% inhibition of chitinase activity
- Figure 6 demonstrates the concentration-related effect of test compound X on wild-type C elegans chitinase activity in synchronous culture m duplicate At 10 ⁇ M, test compound X inhibits chitinase activity by approximately 55%
- Figure 7 illustrates the concentration-related effect of test compound Y on wild-type C elegans chitinase activity in synchronous culture in duplicate At 10 ⁇ M, test compound Y inhibits chitinase activity by approximately 60%
- Figure 8 shows the inhibition of chitinase enzyme activity by test compound X after one hour incubation At 10 ⁇ M, test compound X inhibits chitmase by 10-25% of the control
- Figure 9 shows the inhibition of chitmase enzyme activity, in duplicate, by test compound Y after one hour incubation At 10 ⁇ M , test compound Y inhibits chitmase by 0-3% of the control
- Figure 10A shows an exemplary dose-response curve for a chitinase assay
- Figure 10B shows an exemplary dose response curve for the same compound acting on HEK125 3 cells ("X"- MTT cell viability assay, open triangle- soluble APP levels, closed square- A ⁇ 42 levels, closed diamond- A ⁇ 40 levels)
- Figures 11, 12A and 12B show Western blot analyses of APP processing in HEK125 3 cells or mu ⁇ ne N2A-App cells (N2A-Appl in Figure 12B)
- the invention provides rapid, versatile and reliable methods of screening for candidate compounds such as therapeutics that modulate the egg laying behavior of nematodes such as C elegans
- candidate compounds such as therapeutics that modulate the egg laying behavior of nematodes such as C elegans
- the significance of the invention is partially found m the positive correlation that exists between egg laying defects in nematodes and mammalian disorders or diseases such as Alzheimer's disease, cardiopulmonary diseases and disorders, and Ras-inducible cancer, among others
- the invention also relates to methods for identifying candidate compounds for the treatment of these disorders and diseases
- the power and speed of the methods of the inv ention result from the discovery that chitmase, an enzyme found within nematode eggs, is released into nematode cultures in direct proportion to the capacity of the worms to lay eggs, not merely in direct proportion to the eggs that subsequently hatch.
- nematodes that produce eggs with a normal or wild-type capacity to hatch, but which have an inability to lay such eggs are eventually consumed by the internally hatched offspring. Contrary to expectations that cultures of such organisms would have elevated chitinase levels resulting from egg hatching and progressive destruction of the parents, chitinase levels were not elevated. Further, the methods of the invention can be performed using cultures of free-living nematodes such as C. elegans, whose food source is bacteria and whose cultures therefore contain these organisms, which often release a variety of destructive enzymes such as proteases.
- the invention makes available a rapid, easy and versatile approach to screening for candidate compounds such as therapeutic drugs effective in treating a variety of mammalian disorders and diseases.
- the methods of the invention are also suitable for identifying compounds that are potential risk factors for developing, prolonging or exacerbating one or more mammalian diseases or disorders.
- the methods of the invention avoid the need to use potentially demanding cell cultures in the initial screens and, in using nematodes. the methods avoid the time-consuming and costly need to visually inspect cultures for evidence of egg laying.
- the significance of the invention is apparent in its many and varied embodiments. Because each of the specific members of the chitinase family of enzymes is found within nematode eggs, the methods can be performed by measuring general chitinase activities in culture, or by measuring any or all specific chitinase enzymes found in nematodes. Further, the screening methods of the invention are used to identify modulators of any mammalian disease and/or disorder shown to be related, genetically, biochemically, or otherwise, to nematode egg laying behavior. Examples of such mammalian disorders and/or diseases include, but are not limited to, Alzheimer's disease, cardiopulmonary diseases and disorders, and such forms of cancer as Ras-inducible cancer, among others.
- the modulators or candidate compounds are present in a nematode culture at concentrations ranging from 0.03 to 30 micromolar, or from 0.03 to 10 micromolar.
- the methods of the invention secure the benefit of the thorough genetic investigation of the free-living nematode C. elegans, for which many distinct and useful genotypes and phenotypes are known and available.
- a wild-type strain of C elegans may be used to generally screen for compounds that lower chitinase levels in culture, due to interference or inhibition of egg laying.
- elegans mutants are used to target the screening methods to the identification of candidate compounds useful in the modulation or treatment of particular diseases or disorders, such as Alzheimer's disease.
- a sel-12 mutant strain of C. elegans exhibits defective egg laying, which may be effectively reverted, in part or full, by a candidate compound, with that effective reversion being detected as an increase in the chitinase levels in culture.
- a lin-l 2(d) gain-of-function mutant is used, and compounds modulating chitinase levels by changing them to levels approaching or exceeding the wild-type level include compounds that inhibit Sel-12, which interacts with Lin-12.
- the invention extends to screening methods using nematode strains containing mutations in a potassium channel gene, ras, and other genes associated with egg laying defects.
- the methods of the invention contemplate nematodes containing heterologous orthologs of any one or more of the nematode genes associated with egg laying defects. Further, the invention contemplates screens for toxicity to eliminate candidate compounds that inhibit egg laying by killing the adults.
- the present invention descnbes a screening assay that may be used, foi example, as part of a drug discovery piogram to identify a putative therapeutic compound
- the present invention contemplates the use of the screening assays of the present invention to screen for such compounds that modulate (increase or decrease activity) of chitmase activity
- the invention includes pharmaceutical compositions comp ⁇ sing a candidate compound in an amount effective in modulating or treating one or more mammalian diseases or disorders associated with nematode egg laying
- the pharmaceutical compositions also include any pharmaceutically acceptable excipient, carrier, diluent, and/or adjuvant known m the art
- the present invention provides methods of screening for stimulators of egg laying activity by monito ⁇ ng chitmase activity in the presence and absence of the candidate compound and compa ⁇ ng such results It is contemplated that this screening technique will prove useful in the general identification of a compound that will serve the purpose of promoting, augmenting or increasing a therapeutic effect in at least one of a va ⁇ ety of disorders including, but not limited to, Alzheimer's disease, Ras-mediated cancer, non-Ras-mediated cancer, cardiovascular disorders, and the like.
- the screening methods of the invention can thus be employed to identify any compound whose therapeutic effect may be monitored by a conventional egg laying assay
- a conventional egg laying assay To this end, there are, as noted earlier, a very large number of genes and thus gene products which are associated with phenotypic alterations of egg laying in C elegans
- the use of this screen is suitable for use with any such nematode strain, provided that egg laying behavior is the nematode property being measured
- the present invention is directed to a method for determining the ability of a candidate compound to modulate a particular disease or disorder
- This screen takes advantage of the present discovery that the egg laying phenotype of a C elegans culture may be monitored using a chitmase assay As such, monito ⁇ ng the chitmase activity of such a culture in the presence and absence of a candidate compound will provide information regarding the beneficial or detnmental effects of a given compound on the egg laving properties of the cultuie,
- a candidate compound as being capable of modulating egg laying activity in the assay above, one would measure or determine the chitmase activity in the absence of the added candidate compound One would then add the candidate compound to the cell culture and determine the activity in the presence of the candidate compound A candidate compound which increases or decreases the activity relative to that observed in its absence is indicative of a candidate compound with desired modulatory capability
- Such assays may advantageously identify modulators that are either inhibitors of egg lay activity or, alternatively, are stimulators of egg laying activity, by identifying those compounds that decrease or increase chitmase activity, respectively
- Another distinct aspect of the invention is a screening assay for candidate compounds that alter the egg hatching outside the body of C elegans, thereby increasing or decreasing the amount of chitmase activity present in a culture
- Such assays are performed using cultures of non-parasitic nematodes and are based on the positive correlation of egg hatching and chitmase enzyme activity in cultures of these nematodes
- the candidate compound screening assays are straightforward to set up and perform A candidate compound contacts a C elegans culture under conditions suitable for chitinase expression, processing and/or trafficking, given that particular C elegans strain
- the candidate compound is admixed with the cell In this fashion the ability of the candidate inhibitory compound to reduce, abolish, or otherwise diminish a biological effect mediated that manifests as a defective egg laying phenotype in a C elegans culture
- Effective amounts in certain circumstances are those amounts of a compound, substance, or agent that are effective in reproducibly altering a given nematode egg laying event relative to that event m the absence of the compound, substance, or agent Compounds that achieve significant desired changes m activity are used (e g , as measured by an generally accepted statistical parameter)
- Significant changes in chitinase activity are represented by an increase, or decrease, in chitmase activity of at least about 30%-40%, and most preferably, by changes of at least about 50%, with higher values of course being possible
- the invention also extends to the candidate compounds themselves, identified by one of the claimed screening methods
- the term "candidate compound” refers to any molecule that is suspected of being capable of modulating egg laying activity
- the candidate compound may be a protein or fragment thereof, a small organic molecule, or even a nucleic acid molecule
- the most useful pharmacological compounds identified through application of the screening assay will be compounds that are structurally related to other known compounds that have been identified through an egg laying assay and thus may be termed known modulators of egg laying activity
- the active compounds may include fragments or parts of naturally occurring compounds or may be only found as active combinations of known compounds which are otherwise inactive However, p ⁇ or to testing of such compounds in humans or animal models, it ill be necessary to test a variety of candidates to determine which hav e potential
- the active compounds may include fragments or parts of natuially occurring compounds or may be found as active combinations of known compounds which are otherwise inactive
- the present invention provides screening assays to identify compounds which stimulate or inhibit egg laying and ultimately have, or are developed through drug design to have, therapeutic efficacy in the treatment of a mammalian disease or disorder It is proposed that compounds isolated from natural sources, such as animals, bacteria, fungi, plant sources, including leaves and bark, and ma ⁇ ne samples may be assayed as candidates for the presence of potentially useful pharmaceutical compounds
- the pharmaceutical compounds to be screened could also be de ⁇ ved or synthesized from chemical compositions or man-made compounds
- the candidate compound identified by the present invention may be a polynucleotide, a polypeptide, e g , antibodies
- the screening assays of the invention are amenable to numerous high throughput screening (HTS) assays known m the art
- HTS high throughput screening
- the compounds used in the screening assays, and particularly m the HTS assays may be identified from hbra ⁇ es of chemical compounds
- bra ⁇ es used for the identification of small molecule modulators including chemical libraries, natural product hbra ⁇ es, and combinatorial libraries comprised of random or designed peptides, ohgonucleotides, or organic molecules
- Chemical libraries consist of structuial analogs of known compounds or compounds that are identified as hits or leads via natural product screening or from screening against a potential therapeutic target
- Natural product libraries aie collections of products from microorganisms, animals, plants, insects, or marine organisms which are used to create mixtures for screening by, e g , fe ⁇ nentation and extractions of broths from soil, plant or ma ⁇ ne organisms
- Natural product libraries include polypeptides, non- ⁇ bosomal peptides and non-naturally occur ⁇ ng va ⁇ ants thereof
- Combinatorial libraries are composed of
- the goal of rational drug design is to produce structural analogs of biologically active compounds, substances or agents, e g , polypeptides or compounds with which they interact (agonists, antagonists, inhibitors, peptidomimetics, and binding partners, among others)
- drugs which are more active or stable than the natural molecules, which have different susceptibility to alteration or which may affect the function of va ⁇ ous other molecules
- one would generate a three-dimensional structure for a given peptide or a fragment thereof This could be accomplished by X-ray crystallography, computer modeling, or by a combination of both approaches
- An alternative "alanme scan” approach involves the random replacement of residues throughout the polypeptide molecule with alanine, followed by screening for modulation of relevant functions using the assays of the invention.
- each library contains a large number of compounds which are screened against a biological target such as an enzyme or a receptor. When a biological hit is found, the compound responsible for the hit is identified. Such a compound, or lead, generally exhibits relatively weak activity in the screen but forms the basis for a more traditional, targeted, medicinal chemistry program to enhance activity.
- the libraries may be prepared using the rapidly developing techniques of combinatorial chemistry or by parallel synthesis (DeWitt et al, Proc. Natl. Acad. Sci. (USA) 90:6909 (1993); Jung et al, Angew. Chem. Int. Ed. Engl., 31 :367-83 (1992); Pavia et al., Bioorg. Med. Chem. Lett. 3:387-96, (1993).
- the compounds to be screened may be from a library based upon a common template or core structure [see for instance Ellman et al., J. Amer. Chem. Soc, 114:10997 (1992; benzodiazepine template), WO 95/32184 (oxazolone and aminidine template), WO 95/30642 (dihydrobenzopyran template) and WO 95/35278 (pyrrolidine template)].
- the template has a number of functional sites, for instance three, each of which can be reacted, in a step-wise fashion, with a number of different reagents, for instance five, to introduce 5 x 5 x 5 different combinations of substituents, giving a library containing 125 components.
- the library will normally contain all or substantially all possible permutations of the substituents.
- the template may be a 'biased' template, for instance incorporating a known pharmacophore such as a benzodiazepine ring or an 'unbiased ' template, the choice of which is influenced more by chemical than biological considerations.
- the present invention may be used to identify lead compounds for drug discovery.
- lead compounds may be generated by random cross-screening of single synthetic compounds made individually in the laboratory or by screening extracts obtained from natural product sources such as microbial metabolites, marine sponges, and plants.
- the compounds may be generated through rational drug design based on the structure of known biologically active compounds and/or their sites of biological action. This has now been complemented by the powerful techniques of computer-assisted drug design.
- the goal of rational drug design is to produce structural analogs of biologically active molecules of interest.
- Such technologies have the potential to yield thousands of compounds for a particular indication, and each of the compounds may be advantageously screened for potentially beneficial effects using the screening assays of the present invention.
- the activities of the candidate compounds identified by the screens of the present invention may then be confirmed by screening against strains with suppressors for loss-of-function mutants of a given target. Additionally, it is contemplated that the activities of these candidate compounds may be further confirmed by performing additional screens to monitor the effects of the candidate compounds in mammalian cells exhibiting the particular measurable trait of a disorder to be treated by the compound.
- Example 1 discloses a C. elegans chitinase assay
- Example 2 describes a chitinase assay using a C. elegans strain having a defect in the presenilin pathway
- Example 3 provides a chitinase assay using a C. elegans strain having a potassium channel defect
- Example 4 discloses a chitinase assay using a C.
- Example 1 C. elegans Chitinase Assav
- C elegans cultuie medium was examined to deteimine if chit ase activity could be reliably detected in a medium containing a bactenal food source, such as E colt All strains of C elegans used in the examples descnbed herein, including the wild-type N2 strain, are available thiough the Caenorhabditis Genetics Center at the University of Minnesota
- the emiched peptone medium based on the formulation of Schachat et al , Cell 15 405-411 (1978), contained 1 2 g NaCl, 20 g Bactopeptone, 1 ml cholesterol (5 mg/ml m ethanol), 1 ml 1 M MgSO 4 »7H 2 O, 25 ml 1 M KH 2 PO 4 (pH 6), and 25 g Bactoagar per liter of glass-distilled water Twenty millihters were added to each 100 x 20 mm pet ⁇ dish, 100 ml were added to each 150 x 25 mm pet ⁇ dish
- the NGA medium contained 3 g NaCl, 2 5 g Bactopeptone, 1 ml cholesterol (5 mg/ml in ethanol), 1 ml 1 M CaCl 2 , 1 ml 1 M MgSO 4 '7H 2 O, 25
- E coh broth medium contained 8 g NaCl, lOg Bactotryptone, 5 g yeast extract, 5 mg thymidme and 10 mg cysteme per liter of glass-distilled water
- E coh broth medium contained 8 g NaCl, lOg Bactotryptone, 5 g yeast extract, 5 mg thymidme and 10 mg cysteme per liter of glass-distilled water
- Ten ml ahquots were dispensed into scintillation vials, autoclaved, and stored at 4°C
- E coh broth culture was used to provide food for C elegans on solid media (e g , en ⁇ ched peptone or NGA in pet ⁇ dishes or 96-well plates)
- solid media e g , en ⁇ ched peptone or NGA in pet ⁇ dishes or 96-well plates
- One ml of a 4-day-old E coh broth culture was spread on each NGA or peptone agar dish (150 x 25 mm) while 200 ⁇ l ot broth as spiead on 100 ⁇ 20 mm plates
- the agai containing E coh w as stored for one week at room tempeiatuie in a dra er beiore being inoculated with worms C elegans w ere transferred once a week onto new peptone or NGA agar plates coated containing E coh inoculated using standard techniques
- Strains of C elegans were maintained in a humid, low-temperature incubator set at 20°C
- Chitinase assays of nematode cultures are performed usmg either synchronous or asynchronous cultures
- the worms were first harvested when gravid or full of eggs Harvesting was accomplished by washing each agar dish twice with 5 ml of ste ⁇ le M-9 buffer for 100 x 20 mm dishes (7 5 ml for 150 x 25mm peptone dishes) and the washes were put into a 15 ml ste ⁇ le cent ⁇ fuge tube
- the worms were cent ⁇ fuged in a Beckman cent ⁇ fuge (TJ-6) at 1000 rpm (140 x g) for 2 minutes
- the supernatant was removed and the pellet was resuspended in 10 ml of M-9 buffer
- the resuspended pellet was cent ⁇ fuged at 1000 rpm for 2 minutes
- cultures w ere prepared in individual wells of 96-well plates.
- Medium for these wells contained 75-90 ml of sterile M-9 buffer, 10-25 ml of inoculated E. coh broth, 2 mg sulfamefhoxazole, 1 mg trimethoprim, and 100 ⁇ l of a methanol solution containing 5 mg cycloheximide and 10 mg chloramphenicol per 100ml volume.
- the exact amount of E. coli broth added to the medium was determined by the optical density reading at 570 nm to obtain 1.2 OD for 3.6 ml of inoculated E. coh broth.
- the 1.2 OD was divided by the optical density reading of the E. coli broth and multiplied by 2 for synchronized cultures or 1 for unsynchronized cultures to determine the number of bottles of E. coli broth to be used in the test plates.
- the volume of M-9 buffer was adjusted by the amount of E. coli broth added.
- the primary assay volume in each well of the 96-well plate was 200 ⁇ l, which consisted of 161 ⁇ l of the test culture medium, 6 ⁇ l of M-9, 30%. DMSO control or a test compound at 300 ⁇ M, and 33 ⁇ l of the worm suspension.
- N2 worms from synchronized cultures were diluted in M-9 and 33 ⁇ l were placed on a glass slide for worm counting under a light microscope.
- the nematodes were diluted with M-9 until there were 50-90 worms per 33 ⁇ l. Worms were the final component added to the wells of the test plates.
- the test culture medium volume was 147 ⁇ l
- the volume of nematodes was 33 ⁇ l, diluted where necessary as described above.
- elegans were done with unsynchronized cultures. After the worms became gravid and had LI larvae in the test plates, as determined by visual inspection of control wells, the cultures were subjected to a fluorometric chitinase assay.
- chitinase activity assays are conducted within 12 to 24 hours of egg laying, to minimize the time between test compound addition and completion of the assay.
- assays were conducted by transfe ⁇ ing 10- 100 ⁇ l (a sufficient volume to contain detectable chitmase activity) of cultuie supernatant from indi idual w ells of a 96-well macer plate
- 96-well plates were typically used, one of ordinary skill in the art will recognize that 24-well plates, 384-well plates, and a great variety of other containers would be suitable for use in practicing the methods of the invention
- To the aliquot of culture supernatant was added 10 ⁇ l of a DMSO solution containing 0 8 mM 4-methylumbelhferyl ⁇ -D-N,N',N"-t ⁇ acetylch ⁇ to-t ⁇ os ⁇ de (Sigma Chem Co , St Louis, MO)
- any labeled substrate known m the art may be used, e g , fluoroge c, radiomet ⁇ c or colo ⁇ met ⁇ c labeled chi
- the sel- ⁇ 2 (GS1214) C elegans strain is a presenilin mutant, which car ⁇ es a loss-of- function mutation in the sel-12 gene encoding presenilin- 1 Because the
- Example 3 Chitinase Assays- Potassium Channels To demonstrate that the chitinase assay could be used as a rapid and accurate measure of egg laying defects generally, rather than the subset of egg laying defects directly related to presenilin defects, chitmase assays were performed on cultures of C elegans strains exhibiting egg laying defects due to mutations outside the presenilin pathway proper In particular, C elegans strains n728 (DT6716) and n2332 (MT6011), each containing an egl-36 allele which confers a K 3 potassium channel defect, w eie subjected to the chitmase assay of the invention These two egl-36 strains are partially deficient in egg laying as a result of defects in the ability of the enteric and egg-laying muscles to contract (Johnstone et al , Neuron 19 151 -164 (1997)) The strains were obtained from the Caenorhabditis Genetics Center, University
- Chitmase assays are also performed to identify modulators of Ras, an oncogene product implicated in a va ⁇ ety of mammalian cancers
- Compounds that cause an Egl phenotype in C elegans could act by inhibiting the function of the nematode Ras protein, either directly or through inhibition of farnesyltransferase C elegans maintenance, synchronization where desired, cultu ⁇ ng for assay purposes, and culture assays for chitmase activities are performed as desc ⁇ bed in Example 1
- Re-testing positive compounds in cultures of C elegans strains that either over-express the wild-type nematode Ras protein or express an activated Ras mutem will distinguish compounds that act by directly inhibiting Ras function from those compounds that act at some other site that cont ⁇ butes to this phenotype
- Chitmase assays using a w ild-type nematode stiain, such as C elegans N2 may be used to identify compounds that inhibit chitmase activity, thereby identifying chemicals that aie potential risk factors for symptoms associated with a variety of mammalian disorders or diseases, such as Alzheimer's disease
- Such assays were conducted, using the materials and methods described in Example 1 , along with the introduction of test compounds as described below
- test compounds were individually dissolved in DMSO to a concentration of 10 mM and 50 ⁇ l of each solution was added to separate wells of a 96-well plate Plates typically contained solutions of 88 distinct compounds, with 8 wells reserved for DMSO controls By se ⁇ al dilution with sterile M-9 buffer into fresh 96-well microtiter plate wells, 300 ⁇ M solutions of each test compound were prepared These test compound solutions were then used in the 96-well plate embodiment of the screening methods of the invention, as desc ⁇ bed in Example 1
- test compounds such as test compounds X and Y, were incubated in a low-temperature incubator at 20°C for 1 hour at 0 03, 0 1, 0 3, 1, 3, and 10 ⁇ M The test compounds were then subjected to the chitinase assay, in duplicate, to determine whether these compounds inhibited chitinase directly The activity of these compounds was compared to controls, ensu ⁇
- an assay for egg laying by measu ⁇ ng chitinase was tested in wild-type C elegans (N2 strain), sel-12 presenilin mutants (see Example 2), and two egl-36 potassium-channel mutants (see Example 3)
- the sel-12 mutations cause a nearly complete cessation of egg laying, while the egl-36 strains were significantly (p ⁇ 0.001 ). although incompletely, defective in egg laying, in comparison to the wild-type N2 strain of C. elegans.
- Approximately 1 1,000 compounds were screened at 10 ⁇ M for suppression of egg laying by wild-type womis, and several compounds showed some suppression of egg laying behavior.
- Active compounds in the N2 worm screen were defined as those that reproducibly yielded a 50% reduction in chitinase activity based on the statistics of the distribution.
- the N2 worm screen identified compounds inhibiting chitinase activity with fairly high specificity (18 potential inhibitors in 10,780 compounds tested, an identification rate of 0.2%).
- the most active compound in the N2 worm screen had an IC 50 of 100-300 nM and a maximal inhibition of 56% of the wild- type chitinase activity. A subset of these inhibitors is expected to block presenilin function. Thirty-seven potential hits were identified in the primary screen.
- exemplary compounds for use in the screening methods of the invention include chloroquine (i.e., 7-chloro-4,4-diethylamino-2- methylbutylamino quinoline), primaquine (i.e., 8-(4-amino-l-methylbutylamino)- 6-methoxyquinoline), and the other compounds active in modulating APP processing as disclosed in U.S. Pat. No.
- 5,348,963 the mono- (e.g., 4- aminopyridine) and di-aminopyridines disclosed in U.S. Pat. No. 5,580,580, as well as the pyrimethamine, cromolyn sodium, and erythromycin disclosed in U.S. Pat. No. 5,567,720.
- U.S. Pat. Nos. 5,348,963, 5,580,580, and 5,567,720 are incorporated herein by reference in their entireties.
- Lin- 12(d) worms carry an activating mutation in the Lin- 12 receptor which causes such worms to be defective for egg laying (Sundaram et al , 1993)
- This strain was purchased from the Caenorhabditis Genetics Center at the University of Minnesota
- the hn- 12(d) mutation causes activation of signaling by Lm-12 through the Lm-12/Notch signal transduction pathway This activated signaling produces a defect in egg laying which can be partially rescued by sel-12 loss-of- function mutations (Levitan et al , Nature 377 351-354 (1995))
- the Lin- 12(d) C elegans system provides another distinct aspect of the invention, the maintenance, synchronization, nematode cultu ⁇ ng, and assaying of those cultures were performed as described m Example 1
- 1,700 compounds have been directly screened for modulation of chitinase activity in a primary screen using the hn- 12(d) system, additionally, the 16 compounds
- Candidate compounds identified as modulators using a chitinase assay according to the invention are further tested in a mammalian cell line, such as the human embryonic kidney cell line HEK125.3, a derivative of HEK 293 cells engineered to express APP.
- a mammalian cell line such as the human embryonic kidney cell line HEK125.3, a derivative of HEK 293 cells engineered to express APP.
- a mammalian cell line such as the human embryonic kidney cell line HEK125.3, a derivative of HEK 293 cells engineered to express APP.
- any mammalian cell line known in the art to express APP may be used in the mammalian screening assay.
- any mammalian cell line known in the art to express APP may be used in the mammalian screening assay.
- APP processing assay known in the art may be used., including, but not limited to, animal assays, such as assays involving transgenic mouse models.
- 125.3 cells derived from HEK293 cells, were transformed with a bicistonic vector derived from pIRES- EGFP(Clontech) containing the App695-Sw-KK coding sequence, an internal ribosome entry site, and an enhanced green fluorescent protein coding sequence in the second cistron. Yan et al. (1999).
- the 125.3 cells were grown in DMEM (high glucose and without sodium pyruvate) medium supplemented with 10% fetal bovine serum, IX antibiotic- antimycotic, 1 mM sodium pyruvate, and 400 ⁇ g/ml G418 in a humidified incubator at 37°C with 5% CO,.
- the medium was aspirated from the T75 flask and the cells were rinsed with 10 ml lx PBS without calcium or magnesium.
- the PBS was then removed by aspiration and 5 ml of 0.05% Trypsin EDTA was added to the flask and allowed to remain in contact with the cells for 2-3 minutes at room temperature.
- the five millihters of trypsinized cells were added to 35 ml of medium and centrifuged at approximately 1000 rpm (140 x g) for 3-5 minutes. The medium was aspirated and cells were resuspended in 10-12 ml of medium. The cells were then either passaged into other T75 flasks (a 1 : 10- 1 : 12 dilution with a final volume of 10 ml) or counted on a hematocytometer with a final cell density of 5 x 10 3 cells/ml. Cells (100 ⁇ l per well) were plated on Costar 96 Cell Culture Cluster plates. The next day (Day 2), an additional 100 ⁇ l of medium was added to each well of the 96-well plate.
- test compounds were solubilized in DMSO at 10 mM.
- the compounds were diluted to 30 ⁇ M in medium.
- the two hundred microliter volume was removed by pipette from the cells and the volume was completely replaced with medium containing drug.
- the test plates were prepared in duplicate in which one plate was used for the 3 different enzyme immunoassays (i.e., EIAs).
- conditioned media were diluted 1 :20 and 1 :2, respectively, with 1% BSA in 0.05% of Tween20 in the soluble APP a fragment (sAPP , the APP fragment resulting from ⁇ -secretase cleavage between amino acids 17 and 18 of A ⁇ ) EIA; the conditioned medium was diluted 1 :2 with 1%> BSA in 0.05% of Tween20 in Dulbecco's phosphate-buffered saline without calcium chloride or magnesium chloride.
- the duplicate plate was used in a MTT cell viability assay. After 48 hours, the supernatant from one of the duplicate test plates was aliquoted into -->->- another Costar 96 Cell Culture Cluster plate and stored at -80 C until the 3 different EIAs were perfonried.
- the EIA for A ⁇ 42 was performed as described (Pirttila et al., Neurobiol. of Aging 18: 121-27 (1997)).
- the sAPP assay was performed using the monoclonal antibody 22C1 1 (Boehringer-Mannheim Corp.) to capture sAPP ⁇ , with monoclonal antibody 6E10 (Senetek) used as the detecting antibody.
- Toxicity of one other compound confounded the determination of its effects on APP processing.
- the six active compounds inhibited release of both A ⁇ 40 and A ⁇ 42 by about the same extent. Effects on sAPPcc release were variable. Two of the compounds had no effect on sAPP ⁇ release, one compound stimulated sAPP ⁇ release by 250%). The remaining four compounds decreased sAPP ⁇ release.
- Dose-response curves were determined for each of the active compounds. Two of the compounds showed IC 50 values in the micromolar range; all began to show toxicity at doses greater than or equal to 30 ⁇ M, as assessed by reduction of MTT. For all of the compounds, the IC 50 s for reduction of either A ⁇ 40 or A ⁇ 42 were similar. Processing of APP at the ⁇ -, ⁇ -, or ⁇ -secretase sites should create fragments containing 99, 83, or 40 amino acids comprising the C-terminus of APP.
- antibodies to the C-terminus of APP generally identify the 99- (C- Terminal Fragment-99 or CTF-99) and 83-amino-acid (CTF-83) fragments resulting from ⁇ - and ⁇ -secretase processing, respectively. For reasons unknown, the 49-amino-acid fragment that should result from ⁇ -secretase processing is not detected.
- Western blot analysis Figures 11 , 12A, and 12B
- an antibody directed against the C-terminus of APP identified full-length APP, several unidentified fragments of 20-40 kDa, and a major fragment of about 9 kDa corresponding to CTF-99.
- APP piocessmg assays were conducted using mouse N2A-App cells Several of the compounds alter APP processing intermediates in the mouse N2A-App cells as well as in the human HEK125 3 cells, as shown in Figures 1 1 , 12A and 12B Both cell lines have been transfomied with the same plasmid (desc ⁇ bed above) which directs expression of APP695, having the Swedish NL- ⁇ KM mutation and a C- terminal di-lysme motif In both 125 3 cells and N2A-APP cells, one compound increased accumulation of an APP CTF corresponding in size to CTF-99 Two other compounds increased accumulation of an APP CTF corresponding in size to the ⁇ -secretase product, CTF-83, with concomitant stimulation of sAPP ⁇ release
- PKC PKC activation
- Activation of PKC m cellular assays of APP processing stimulates entry of APP into the ⁇ -secretase processing pathway
- this candidate compound also increased the CTF-83 ⁇ - secretase processing product of APP in treated cells
- the compound is also active in assays of phosphohpase A2 inhibition, which suggests that it is acting through modulation of membrane hpid composition Loss of PS 1 activity in PS 1 null mouse neurons reduces A ⁇ processing but has little or no effect on the secretion of sAPP ⁇ (DeStrooper et al..
- APP expression in human cells was also assayed using Western blot analyses.
- a human embryonic kidney cell line, HEK125J cells, or the Neuro2A- APP1 cell line expressing APP695-Sw-KK were grown in 100 mm plates in modified Eagle's medium (i.e., MEM) supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 1 mM non-essential amino acids, and 400 ⁇ g ml G418. After cells were grown to about 50-70% confluency, individual test compounds were added to the medium at a final concentration of 10 ⁇ M. The compounds were left in contact with the cells for 48 hours before preparation of the cell lysates.
- MEM modified Eagle's medium
- lysates were transferred to 15 ml conical tubes and centrifuged at 1 ,500 rpm (340 x g) for 5 minutes to remove the medium. The cell pellet was washed once with conventional phosphate-buffered saline (i.e., PBS). Cells were lysed in lysis buffer (10 mM HEPES, pH 7.9, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 0.1 mM sodium vanadate, and 1%
- Nonidet P-40 The lysed cell mixtures were centrifuged at 5000 rpm (2,040 x g) and the supematants were stored at -20°C. Protein concentrations were determined with the Bio-Rad Protein Assay (Bio-Rad Laboratory, Hercules, CA). Equal amounts of protein (50 ⁇ g) were used for electrophoretic analyses on 4-12% Tricine gels (Novex, San Diego, CA) followed by protein transfer to nitrocellulose membranes.
- Antibody 6E10 (Senetek) is also used for detection of fragments, such as CTF-99.
- CTF-99 fragments
- lmmunoblott g cells were washed once with cold PBS, released horn the dish by scraping into PBS, and the cells were collected by centrifugation (2,000 rpm (593 x g) for 3 minutes) The pellets were collected from 6 w ell tissue culture plates and resuspended in 0 5 ml cold IPB lysis buffer (10 mM T ⁇ s-HCl, pH 7 5, 5 mM EDTA.
- Membranes were blocked in TBS-T (25 mM T ⁇ s-HCl (pH 7 5/ 0 15 M NaCl/0 1% Tween 20) containing 0 1% BSA (Sigma) and 5% nonfat milk (Bio- Rad) for 2 5 hours at room temperature
- Membranes used to detect CTF-99 were probed with a biotmylated 6E10 monoclonal antibody (Senetek) at 1 1000 dilution in TBS-T containing 0 1 % BSA and 5% nonfat milk overnight at 4°C
- Each membrane was washed 3 x 10 minutes with TBS-T and then probed with secondary antibody (cat anti-mouse IgG HRP (Santa Cruz), 1 5000 dilution containing 0 1% BSA and 5% nonfat milk) for 1 5 hours at room temperature
- Membranes used to identify aspartyl protease (i e , Asp2) were probed under the same conditions as desc ⁇ bed above P ⁇ m
- Western blot analyses of treated lysates can be used to distinguish between potential beta and gamma secretase inhibitors.
- Western blot analysis also distinguishes between drug effects on cleavage events versus trafficking or maturation. Consequently, Western blot analysis provides a useful secondary screen for drugs that appear to be active in A ⁇ production.
- Enzyme-linked immunosorbent assays were also used to monitor the expression of APP, including the production of A ⁇ -40 and A ⁇ -42.
- the ELISA for A ⁇ -40 and A ⁇ -42 was performed as described (Mehta et al., Neurosci. Lett. 241 13-16 ( 1998))
- the sAPP assay was perfonned using monoclonal antibody 22C 1 1 to capture sAPP, with antibody 6E10 used as the detecting antibody
- the assays of the invention could be used in screens for general nematode toxicity as well, since compounds that kill orms will result in low chit ase levels in the culture Howev er, most general screens that use C elegans visually examine the worms foi effects on behavior and motility as well as viability and reproduction Because compounds that reduce egg-laying in cultures of wild-type animals could be simply toxic, positive wells are visually checked to determine if egg laying has been selectively affected For microscopic inspection, an aliquot of the culture supernatant is transferred to a fresh 96-well plate with an automatic or robotic pipettor, thereby preserving the original culture for quick visual inspection of positive wells
- a sel-12 mutant strain of C elegans was used to screen for compounds that would inhibit Hop-1, thereby creating a phenocopy of the lethal hop-1, sel-12 double mutant
- a screen was developed to identify compounds that would effectively render C elegans Hop-1 , which would be lethal only to sel-12 worms and not to wild-type N2 worms
- cultures were not synchronized Asynchronous cultures of sel 12 worms, producing a sufficient number of eggs that hatched, were used in the assay Cultures were grown on soft agar in 35 mm dishes
- One tested compound caused a malformation of eggs developing within the gonad of sel-12 adults Rather than seeing the normal linear array of well-formed eggs, these eggs were larger and lacked definition
- Two other tested compounds reduced the numbers of eggs within sel-12 adult worms and those eggs were larger than normal Three other tested compounds had no visible effect
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00937874A EP1180165A2 (en) | 1999-05-27 | 2000-05-26 | A nematode drug screen for modulators of mammalian disorders |
AU52992/00A AU5299200A (en) | 1999-05-27 | 2000-05-26 | A nematode drug screen for modulators of mammalian disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13617399P | 1999-05-27 | 1999-05-27 | |
US60/136,173 | 1999-05-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000073493A2 true WO2000073493A2 (en) | 2000-12-07 |
WO2000073493A3 WO2000073493A3 (en) | 2001-05-31 |
Family
ID=22471665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/014678 WO2000073493A2 (en) | 1999-05-27 | 2000-05-26 | A nematode drug screen for modulators of mammalian disorders |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1180165A2 (en) |
AU (1) | AU5299200A (en) |
WO (1) | WO2000073493A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2359358A (en) * | 1999-04-15 | 2001-08-22 | Devgen Nv | Compound screening method |
WO2003097682A1 (en) * | 2002-05-15 | 2003-11-27 | Devgen Nv | Methods for identifying and developing compounds that interact with voltage-gated potassium channels of the kv4 family |
WO2004061096A1 (en) * | 2003-01-07 | 2004-07-22 | Genova, Ltd. | Secreted polypeptide species (fragments from chitotriosidase) reduced in cardiovascular disorders |
WO2006065709A2 (en) * | 2004-12-15 | 2006-06-22 | Schering Corporation | Functional assays for cholesterol absorption inhibitors |
CN105738585A (en) * | 2014-12-09 | 2016-07-06 | 兰州红虫生物工程有限责任公司 | Drug screening kit |
CN105738329A (en) * | 2014-12-09 | 2016-07-06 | 兰州红菌生物技术有限责任公司 | An antitumor medicine screening kit and a using method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032623A1 (en) * | 1997-12-19 | 1999-07-01 | Pharmacia & Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
WO1999032619A1 (en) * | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded rna |
WO2000063427A2 (en) * | 1999-04-15 | 2000-10-26 | Devgen Nv | Compound screening method |
-
2000
- 2000-05-26 WO PCT/US2000/014678 patent/WO2000073493A2/en not_active Application Discontinuation
- 2000-05-26 EP EP00937874A patent/EP1180165A2/en not_active Withdrawn
- 2000-05-26 AU AU52992/00A patent/AU5299200A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032623A1 (en) * | 1997-12-19 | 1999-07-01 | Pharmacia & Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
WO1999032619A1 (en) * | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded rna |
WO2000063427A2 (en) * | 1999-04-15 | 2000-10-26 | Devgen Nv | Compound screening method |
Non-Patent Citations (2)
Title |
---|
GEARY T G (REPRINT) ET AL: "Mechanism-based screening: discovery of the next generation of anthelmintics depends upon more basic research" INTERNATIONAL JOURNAL FOR PARASITOLOGY, (JAN 1999) VOL. 29, NO. 1, PP. 105-112. PUBLISHER: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND. ISSN: 0020-7519., XP000972176 PHARMACIA & UPJOHN INC, ANIM HLTH DISCOVERY RES, 301 HENRIETTA ST, KALAMAZOO, MI 49007 (Reprint) * |
GEARY T G (REPRINT): "APPROACHING HELMINTH BIOLOGY FROM THE MOLECULAR DIRECTION" PARASITOLOGY TODAY, (OCT 1996) VOL. 12, NO. 10, PP. 373-375. ISSN: 0169-4758., XP000972039 PHARMACIA & UPJOHN INC, ANIM HLTH DISCOVERY RES, 301 HENRIETTA ST, KALAMAZOO, MI, 49007 (Reprint) * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2359358A (en) * | 1999-04-15 | 2001-08-22 | Devgen Nv | Compound screening method |
GB2359358B (en) * | 1999-04-15 | 2002-03-27 | Devgen Nv | Compound screening method |
WO2003097682A1 (en) * | 2002-05-15 | 2003-11-27 | Devgen Nv | Methods for identifying and developing compounds that interact with voltage-gated potassium channels of the kv4 family |
WO2004061096A1 (en) * | 2003-01-07 | 2004-07-22 | Genova, Ltd. | Secreted polypeptide species (fragments from chitotriosidase) reduced in cardiovascular disorders |
WO2006065709A2 (en) * | 2004-12-15 | 2006-06-22 | Schering Corporation | Functional assays for cholesterol absorption inhibitors |
WO2006065709A3 (en) * | 2004-12-15 | 2006-08-03 | Schering Corp | Functional assays for cholesterol absorption inhibitors |
CN105738585A (en) * | 2014-12-09 | 2016-07-06 | 兰州红虫生物工程有限责任公司 | Drug screening kit |
CN105738329A (en) * | 2014-12-09 | 2016-07-06 | 兰州红菌生物技术有限责任公司 | An antitumor medicine screening kit and a using method thereof |
CN105738329B (en) * | 2014-12-09 | 2019-05-07 | 费好义 | Screening anti-tumor medicine kit and its application method |
Also Published As
Publication number | Publication date |
---|---|
AU5299200A (en) | 2000-12-18 |
EP1180165A2 (en) | 2002-02-20 |
WO2000073493A3 (en) | 2001-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ashida et al. | A bacterial E3 ubiquitin ligase IpaH9. 8 targets NEMO/IKKγ to dampen the host NF-κB-mediated inflammatory response | |
Fang et al. | NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair | |
Fatouros et al. | Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity | |
Coburn et al. | Anthranilate fluorescence marks a calcium-propagated necrotic wave that promotes organismal death in C. elegans | |
Klassen et al. | An Arf-like small G protein, ARL-8, promotes the axonal transport of presynaptic cargoes by suppressing vesicle aggregation | |
Pir et al. | Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans Tauopathy model | |
Orosz et al. | TPPP/p25: from unfolded protein to misfolding disease: prediction and experiments | |
AU780574B2 (en) | Compound screening method | |
Caillon et al. | Cholesterol modulates the interaction of the islet amyloid polypeptide with membranes | |
Gallrein et al. | Novel amyloid-beta pathology C. elegans model reveals distinct neurons as seeds of pathogenicity | |
Kingtong et al. | ATP-binding cassette multidrug transporters in Indian-rock oyster Saccostrea forskali and their role in the export of an environmental organic pollutant tributyltin | |
Diao et al. | Avermectin induced DNA damage to the apoptosis and autophagy in human lung epithelial A549 cells | |
Thomson et al. | Inducible somatic oocyte destruction in response to rapamycin requires wild-type regulation of follicle cell epithelial polarity | |
He et al. | Ginsenoside Rg1 decreases neurofibrillary tangles accumulation in retina by regulating activities of neprilysin and PKA in retinal cells of AD mice model | |
Uhlig et al. | Identification of a quorum sensing-dependent communication pathway mediating bacteria-gut-brain cross talk | |
Li et al. | Olfactory deficit is associated with mitral cell dysfunction in the olfactory bulb of P301S tau transgenic mice | |
Pattabiraman et al. | Mast cell function in prostate inflammation, fibrosis, and smooth muscle cell dysfunction | |
EP1180165A2 (en) | A nematode drug screen for modulators of mammalian disorders | |
Ellerbrock et al. | Screening for presenilin inhibitors using the free-living nematode, Caenorhabditis elegans | |
US20090208960A1 (en) | Methods for identifyng cellular modulators of disaggregation activity or aggregation activity in an animal | |
WO2008103966A2 (en) | Compositions and methods using toll-like receptors and unc93b | |
Ayyadevara et al. | Functional assessments through novel proteomics approaches: Application to insulin/IGF signaling in neurodegenerative disease' | |
US6787125B1 (en) | Compound screening method | |
US20030154501A1 (en) | Compound screening method | |
Park et al. | Elucidation of the nematicidal mode of action of grammicin on Caenorhabditis elegans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000937874 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000937874 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000937874 Country of ref document: EP |